Join us in welcoming Danielle Meyrick, PhD, MD, Dr. Hakim Bouterfa and Michael Freissmuth, MD as our new Scientific Advisory Board (SAB) to support the further growth of our PreTarg-it® Platform. Their collective expertise will help guide our development of more precise and flexible therapies for cancer.

• Dr. Danielle Meyrick is a clinician, radiopharmaceutical chemist, and biotech executive with 20+ years of experience in clinical development, regulatory strategy, and medical affairs. Her expertise across theranostics, radiochemistry, and commercialization will support the advancement of OncoOne’s radiopharmaceutical therapies and strategic collaborations.
• Dr. Hakim Bouterfa is a life sciences entrepreneur, scientist, and executive with 25+ years of international experience in oncology and radiopharmaceutical development. Having founded and led several life science companies, as well as held senior roles at Novartis and Eckert & Ziegler, he will advise OncoOne on corporate strategy, clinical development, and value creation.
• Dr. Michael Freissmuth is an award-winning pharmacologist and Professor of Pharmacology who previously led the Center of Physiology & Pharmacology and the Institute of Pharmacology at the Medical University of Vienna. An inaugural member of OncoOne’s SAB, he continues to support the development of the company’s biotherapeutics pipeline.

Learn more by reading the full announcement here.